- Post By : Kumar Jeetendra
- Source: PTI
- Date: 29 Oct,2020
- Pros: Quo te partem nusquam salutatus, nobis oratio vel ut. Duo te quod salutatus.
The first set of COVID-19 vaccines that clear clinical trials for rollout to combat the deadly virus are most likely to be imperfect and might not work equally for everyone, the chief of the United Kingdom government’s Vaccine Taskforce has warned.
Kate Bingham, Chair of the UK’s Vaccine Taskforce set up earlier this year to coordinate global efforts in search of a workable vaccine against the novel coronavirus, said it is important to manage expectations since the early discoveries will probably not prove the”silver bullet” that the world is hoping for to get to grips with the pandemic.
“The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but instead reduce symptoms, and, even then, may not work for everyone or for long,” Bingham writes in an article for the medical journal’The Lancet’ this week.
Highlighting that the UK is at the”forefront” of a massive international effort to develop clinically safe and effective vaccines, she struck a note of warning that there are no guarantees that a successful vaccine will be found in any respect.
Vaccination is widely regarded as the only true exit strategy from the pandemic that is currently spreading globally. However, we do not know that we will ever have a vaccine at all. It’s important to guard against complacency and over-optimism,” she writes.
Bingham explains that in the long-term it can be the case that we require different kinds of vaccines for different sets of the global population since the immunity levels differ widely within age groups.
Hence, the life sciences specialist said that the UK’s plan has been to create a diverse portfolio across different formats to have the best chance of providing a safe and effective vaccine,”recognising that many, and possibly all, of these vaccines could fail”.
The UK’s Vaccine Taskforce has secured access to six vaccines, from over 240 vaccines in development, across different formats, from adenoviral vectors to entire inactivated viral vaccines.
The most advanced vaccines, such as those developed by Oxford University and AstraZeneca, BioNTech and Pfizer, and Janssen, are based on book formats where the taskforce said the initial immunogenicity and safety data seems encouraging.
Vaccines based on frequently used vaccine formats, such as adjuvanted protein vaccines developed by Novavax, and by GSK and Sanofi, and inactivated whole viruses developed by Valneva, will not be available until late in 2021.
“The UK is committed to ensuring that everyone in danger of SARS-CoV-2 infection, anywhere in the world, has access to a safe and effective vaccine,” said Bingham.
“No one is safe until we are all safe. Pandemic viruses do not respect national borders,” she said.
Her intervention comes as it emerged this week that the vaccine candidate under development by Oxford University and AstraZeneca has demonstrated a”strong immune response” in most adult groups.
Further details from the ongoing trials are anticipated over the coming weeks, with some reports indicating a rollout in a initial group of people by the end of this year. The coronavirus has murdered over 1.1 million people with 44 million confirmed cases throughout the world up to now.